Bertrand Cayrol
Keine laufenden Positionen mehr
Karriereverlauf von Bertrand Cayrol
Ehemalige bekannte Positionen von Bertrand Cayrol
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Société Innovatech du Grand Montréal | Corporate Officer/Principal | 01.01.1992 | 31.12.1996 |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Direktor/Vorstandsmitglied | 15.12.2009 | - |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private Equity Investor | 01.01.1997 | - |
Ausbildung von Bertrand Cayrol
Ecole Nationale Superieure de Chimie de Toulouse | Undergraduate Degree |
McGill University | Doctorate Degree |
Statistik
International
Kanada | 4 |
Frankreich | 3 |
Operativ
Private Equity Investor | 1 |
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Sektoral
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
Société Innovatech du Grand Montréal | |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Cytheris SA develops and manufactures drugs for immune modulation. It is a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The firm's product CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments: Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients and Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR). Cytheris has locations in France and The United States. The company was founded in January 1999 by Michel Morre and is headquartered in Issy-les-Moulineaux, France. | Health Technology |
- Börse
- Insiders
- Bertrand Cayrol
- Erfahrung